Detection of Somatic Copy Number Deletion of *CDKN2A* Gene for Clinical Practices Based on

Discovery of A Base-Resolution Common Deletion Region

Running title: Detection of somatic *CDKN2A* deletion

Yuan Tian, Ph.D. [1#], Rui Xing, Ph.D. [2#], Jing Zhou[1#], Juanli Qiao, Ph.D. [1], Zhaojun Liu, Ph.D. [1], Liankun Gu[1],

Baozhen Zhang, Ph.D. [1], Youyong Lu, M.D. [2], Dajun Deng, M.D. [1]*

[1] Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Etiology, Peking

University Cancer Hospital and Institute, Beijing, 100142, China;

[2] Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Tumor Biology,

Peking University Cancer Hospital and Institute, Beijing, 100142, China

Equal first authors

*Corresponding author: Dajun Deng, Key Laboratory of Carcinogenesis and Translational Research

(MOE/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Fu-Cheng-Lu #52,

Haidian District, Beijing, 100142, China, Phone:+8610-88196752 (E-mail: dengdajun@bjmu.edu.cn)

Word count: 3127

Abstract

Background: *CDKN2A* is most frequently inactivated by somatic copy number deletion (SCND) in human cancers. An accurate method to detect *CDKN2A* SCND is absent.

Methods: To look for the pattern of *CDKN2A* SCND in cancer cells, interstitial base-resolution deletion/fusion coordinates for *CDKN2A* were extracted from published articles and our whole genome sequencing (WGS) datasets. A multiplex PCR assay was setup to quantify *CDKN2A* copy number and confirmed with WGS and loss of heterozygosity (LOH) assays using gastric carcinoma (GC) samples from two sets of patients (n=156 and 140), respectively.

Results: We characterized a 5.1-kb common deletion region (CDR) from the *CDKN2A/P16^INK4A^* promoter to intron-2 in >90% (83/92) of cancer cell lines and 100% (18/18) of GC samples by WGS. The CDR includes exon-2 that is shared by *P16^INK4A^* and *P14^ARF^* genes. Then, a highly reproducible and quantitative assay, P16-Light, targeted to the CDR was setup with a lower limit of detection at 20%. P16-Light was further compared with WGS (gold standard) and LOH assay by denaturing high performance liquid chromatography. The positive rate of *CDKN2A* SCND by P16-Light was more than two times of that by WGS in GCs from a patients cohort (25.6% vs. 10.9%), and was significantly correlated with each other ($p<0.028$). While *CDKN2A* SCND was significantly associated with GC distant metastasis ($p=0.023$), such association was not observed for *CDKN2A* LOH.

Conclusion: Based on our finding that there is a 5.1-kb CDR within the *CDKN2A* gene, a vary convenient P16-Light assay was setup to detect *CDKN2A* SCND for routine clinical applications.

Key words: *CDKN2A*; common deleted region (CDR); whole genome sequencing (WGS), LOH, gene copy number variations

Background

Somatic copy number deletion (SCND) of the *CDKN2A* gene is a landmark of human cancers (1,2). The frequency of *CDKN2A* SCND detected by single nucleotide polymorphism (SNP) microarray, whole genome sequencing (WGS) or whole exome sequencing (WES) was found to be ranged from 30% to 60% in bladder cancer, melanoma, head and neck cancer, pleural mesothelioma, glioblastoma, and esophageal squamous cell cancer (ESCC) with an average frequency of 13% in pan-cancer datasets in The Cancer Genome Atlas (TCGA) (Figure S1A) (2-6). *CDKN2A* deep-deletion is associated with downregulation of the *CDKN2A* gene expression, while *CDKN2A* amplification is associated with upregulation of the *CDKN2A* gene expression in Pan-TCGA cancers (Figure S1B).

It is well known that genetic *CDKN2A* inactivation contributes to malignant transformation, cancer metastasis, and therapy sensitivity of cancers to drugs, including CDK4/6 inhibitors and their combination with PD-1 blockades (7-11). However, current gene copy number detection methods, including fluorescence-in-situ hybridization (FISH) and WGS or WES, are not sensitive enough or too costly for routine clinical use. While the amplification of oncogenes (such as *EGFR*, c-*ERBB2,* c-*MYC*, and c-*MET*) are increasingly driving decision-making for precise cancer treatments, clinical applications of SCND of tumor suppressor genes, including *CDKN2A*, are still rare owing to the lack of a feasible detection assay.

METHODS

Patients, tissues, and DNA preparation

Frozen fresh GC and paired SM tissue samples were collected from 140 patients in Beijing Cancer Hospital and 156 patients in the WGS study (12). These samples were frozen at liquid nitrogen approximate 30 min post surgical dissection, and then stored at a -80° C refreezor for 2-5 yrs. Clinicopathologic information were also obtained. The 2010 UICC tumor-node-metastasis (TNM) system was used for the classification of these GCs (13). Genomic DNA was extracted from these samples with a phenol/chloroform method coupled with RNase treatment. Concentrations of these DNA samples were determined with NanoVue Plus (Biochrom LTD, Cambridge, UK). DNA samples with OD_{260nm}/OD_{280nm} ratios ranged 1.7-1.9 were used for detection of gene copy number as descrobed below.

Optimized quantitative multiplex PCR assay (P16-Light) to detect CDKN2A copy number

A number of multiplex primer and probe combinations were designed based on the best multiplex primer probe scores for conservative sequences within the CDR in the *CDKN2A* (HGNC: 1787) and *GAPDH* (HGNC:

4141) gene sequences by Bacon Designer 8 software. Multiplex PCR assays were established according to the Applied Biosystems (ABI) TaqMan universal PCR master mix manual. The performances of these assays for the detection of *CDKN2A* copy numbers were compared with each other. Finally, a multiplex primer and probe combination targeted to *CDKN2A* intron-2 was selected (Table 1) and their components' concentrations were optimized. Briefly, each multiplex PCR assay was carried out in a total of 20 μL volume that included 5-10 ng of input DNA, 10 μM of forward and reverse primers and probe for *CDKN2A* intron-2, 10 μM forward and reverse primers and probe for *GAPDH*, and 10 μL of 2 x TaqMan Universal Master Mix II with uracil-N-glycosylase (Kit-4440038, ABI, Lithuania). The PCRs were performed in triplicate in a MicroAmp Fast Optical 96-Well Reaction Plate with a barcode (0.1 mL; ABI, China) with an ABI 7500 Fast Real-Time PCR System. The specific conditions of the PCR were as follows: initial incubation for 10 min at 95°C, followed by 40 cycles of 95°C for 20 sec and 58°C for 60 sec. When Ct value for *GAPDH* input for a sample was 34 or less cycles, this sample was considered as *CDKN2A* SCNV informative. The specificity of PCR reaction was monitored through running gel. Distilled water was used as no template control for each experiment.

Definitions of *CDKN2A CDR* deletion-positive and amplification-positive

We used the genomic DNA from A549 cells containing no *CDKN2A* allele to dilute genomic DNA from RKO cells containing 2 wild-type *CDKN2A* alleles, and then we set the standard curve according to the relative copy number of the *CDKN2A* gene at different dilution concentrations. The ΔCt value and relative copy number for the *CDKN2A* gene were calculated using the *GAPDH* as the internal reference. When the *CDKN2A* copy number in the A549-diluted template was consistently lower than the copy number in the RKO control template, and the difference was statistically significant (t-test, *p*<0.05), it was judged that the lowest dilution concentration was the detection limit of *CDKN2A* deletion (the difference in *CDKN2A* copy number between the 100% RKO template and 80% RKO template spiked with 20% A549 DNA). When the *CDKN2A* relative copy number in a tissue sample was significantly lower or higher than that of the paired SM sample, the sample was defined as somatic *CDKN2A CDR* deletion-positive or amplification-positive, respectively. The 100% A549, 100% RKO, and 20% A549 + 80% RKO DNA mix controls were analyzed for each experiment.

Call for *CDKN2A* interstitial deletion/fusion in the GC WGS datasets

We used Meerkat (http://compbio.med.harvard.edu/Meerkat/) 23 to predict somatic SVs and their breakpoints in WGS datasets (accession numbers, EGAD00001004811 with 36$\times$ of sequencing depth) for

gastric adenocarcinoma samples from 168 patients using the suggested parameters (12). This method used

soft-clipped and split reads to identify candidate breakpoints, and precise breakpoints were refined by local

alignments. *CDKN2A* deletion information was obtained from WGS datasets for 157 GC samples.

Detection of MSI by DHPLC

The microsatellite-specific primers were used to amplify the target microsatellite at the corresponding

annealing temperature (Table 1). Input DNA template (5 ng) were used per PCR interaction. The

microsatellite PCR products were separated with a DNASep Analytic Column using the DHPLC platform

(WAVE[TM] DNA Fragment Analysis System, Transgenomic, Inc., Omaha, USA; FL-detector) at 50 °C to

determine the MSI status of target locus according to the difference in the peak composition and peak area

ratio of each microsatellite locus between GC and paired SM samples. Three microsatellites (*D9S974*,

D9S942, and *D9S1748*) within the *P16* CDR closely flanking fragment were used as markers that represented

the LOH/MSI in the CDR (14-16). The criteria for MSI were as follows: a) in the paired test result, if the

detecting peak disappeared, it was directly determined that MSI occurs; b) if the peak height/area of the

detecting waveform corresponding to the cancer tissue was reduced by >30%, it was determined that MSI

occurs; c) when the two detection peaks coincided together, it was defined as not informative (17-19).

When MSI at least one of three *CDKN2A*-CDR flanking microsatellites was detected in a sample relative to

the normal control, the sample was defined as *CDKN2A* LOH (or gain of heterozygosity, GOH)-positive.

Cell lines and cultures

The human gastric cancer cell line MGC803 (kindly provided by Dr. Yang Ke at Peking University Cancer

Hospital) and the *P16* allele homozygously deleted cell line A549 (kindly provided by Dr. Zhiqian Zhang of

Peking University Cancer Hospital and Institute) were grown in RPMI-1640 medium, and the RKO cell line

containing two wild type *P16* alleles was purchased from American Type Culture Collection and grown in

DMEM media. The medium was supplemented with 10% (v/v) fetal bovine serum (FBS). These cell lines

were tested and authenticated by Beijing JianLian Genes Technology Co., Ltd. before they were used in this

study. STR patterns were analyzed using a Goldeneye[TM] 20A STR Identifiler PCR Amplification kit.

Statistical analysis

Chi-square or Fisher's exact tests were used to compare the proportion of *CDKN2A* SCND or amplification

between different groups of tissue samples. Student t-test was used to compare the proportion of the

CDKN2A gene copy number between genomic DNA samples. All statistical tests were two-sided, and *p* value

less than 0.05 was considered to be statistically significant.

Results

Characterization of a base-resolution *CDKN2A* common deletion region (CDR) in human cancers

It has been previously reported that a homozygous deletion of approximately 170 kilobase pairs (kb), including the *CDKN2A* locus, can be detected in human cancers by microsatellite instability (MSI) analyses (20). To characterize the base-resolution genomic coordinates of *CDKN2A* deletions in cancers, we extracted sequence information of interstitial *CDKN2A* deletions from all available published articles and our sequencing data (Table S1) (21-31). We found a 5.1-kb CDR (chr9: 21,970,277 - 21,975,386, hg19) that spanned from the *P16^INK4a* promoter to intron-2 in 83 (90%) of 92 reported cancer cell lines or tissue samples containing interstitial *CDKN2A* deletions (Figure 1, blue lines). This CDR sequence is exactly the same as the *CDKN2A* deletion fragment in the HCC193 lung cancer cell line (28). The CDR coordinates were also confirmed in our WGS datasets (average sequencing depth, 36×) of 18 (100%) of 18 GCs (12), in which interstitial *CDKN2A* deletions/fusions were identified (Figure 1, purple lines; Table S1).

It is well known that germline *CDKN2A* inactivation can lead to a high predisposition for melanoma and pancreatic cancer (32-34). Interestingly, we found that 14 (93.3%) of 15 *CDKN2A* allelic variants in the Online Mendelian Inheritance in Man (OMIM) database are located within the CDR sequence (Figure S2) (35,36). These phenomena indicate that both inherited and somatic defects of the *CDKN2A CDR* region are cancer drivers.

Both *P16^INK4a* and *P14^ARF* mRNAs are transcribed from the human *CDKN2A* gene at chromosome 9p21, but with different transcription start sites; they share the same exon-2 but have different translation reading frames. Because *CDKN2A* exon-2 located within the CDR is the essential exon for coding P16^INK4a and P14^ARF proteins, the above findings indicate that *P16^INK4a* and *P14^ARF* are co-inactivated in 87% (96/110) of human cancer cell lines and tissues containing *CDKN2A CDR* deletion (Figure 1).

Establishment of a convenient PCR assay (P16-Light) to detect somatic *CDKN2A CDR* deletion

The current clinical method FISH for detecting SCND is composed of a set of biotin-labelled probes which should cover at least 50-kb DNA sequence. Thus, FISH is not a suitable method for detecting the copy number of the 5.1-kb *CDKN2A* CDR. To provide a convenient method for routine clinical use, we designed and experimentally evaluated a set of multiplex quantitative PCR assays and finally optimized the *CDKN2A* CDR-specific quantitative multiplex PCR assay called P16-Light for detecting the copy number of a 129-bp amplicon within *CDKN2A/P16^INK4a* intron-2 (Figure 2A), which covers 86% (94/110) of known *CDKN2A*

deletion fragments (Figure 1).

The copy number of *GAPDH* gene was used as the internal reference (Table 1). Genomic DNA from human A549 cells (with homozygous deletion of *CDKN2A* alleles) and RKO cells (with 2 wild-type *CDKN2A* alleles) were used as *CDKN2A* CDR deletion-positive and deletion-negative controls, respectively. The amplification efficiency of two amplicons in *GAPDH* and *CDKN2A* were very similar (Figure 2B). No template inhibition was abserved when the amount of template DNA was ranged from 10 to 0.63 ng (Figure 2C). The proportions of *CDKN2A* CDR copy number were linearly correlated with the ratios (0 - 100%) of RKO cell DNA and A549 cell DNA in the input mixtures (10 ng/reaction) when the A549 DNA was spiked in at different proportions for the P16-Light analyses (Figure 2D). Furthermore, there was a high reproducibility when DNA with homozygous deletion of *CDKN2A* was present in ≥20% of the cells, which were verified in ten experimental repeats that were performed on different days (Figure 2E). Thus, when the proportion of *CDKN2A* copy number was significantly decreased (or increased) in a sample relative to the paired normal control (t-test, *p*<0.05) in the P16-Light analyses, the sample would be defined as *CDKN2A* SCND positive (or amplification positive).

Comparison of P16-Light with WGS

As we described above, information on interstitial copy number deletion/fusion of the *CDKN2A* gene was extracted from WGS datasets for 157 of 168 GC patients enrolled in a GC genome study and a total of 18 *CDKN2A* deletion/fusion coordinates at the base-resolution were detected in 17 (10.8%) GCs (Table S1). To compare the performance of P16-Light with WGS, we analyzed the status of somatic copy number variations (SCNVs), including SCND and amplification, of *CDKN2A* in 156 of these GCs with enough amounts of genomic DNA samples with P16-Light using the paired surgical margin tissue (SM) as the diploid reference. *CDKN2A* SCND and amplification were detected in 40 (25.6%) and 34 (21.8%) of these GCs, respectively. The P16-Light analysis was confirmed by the WGS results: the frequency of *CDKN2A* SCND (or amplification) by P16-Light was significantly higher (or lower) in 17 GCs containing interstitial *CDKN2A* deletion/fusion than those 139 GCs without (chi-square test, *p*<0.028; Figure 3). These results suggest that there is a significantlyt higher sensitivity for detecting *CDKN2A* SCND by the quantitative P16-Light assay than the hemi-quantitative WGS.

Comparison of P16-Light with LOH/MSI assay

Denaturing high performance liquid chromatography (DHPLC) was a rapid sensitive assay, which could be

used to detect loss of heterozygosity (LOH) of genes (17-19). To compare P16-Light with a sensitive method, we established a DHPLC assay coupled with post-column double-strand DNA fluorescence-labeling device and a fluorescence detector. The fragment separation mode at 50 °C was used to detect microsatellite instability (MSI) of previously reported microsatellite loci within and outside of the *CDKN2A* gene: 3 *CDKN2A*-CDR flanking microsatellites (*D9S974*, *D9S942*, and *D9S1748*) and 3 non-*CDKN2A* microsatellites (*D9S941*, *D9S1749*, and *D9S171*) (Figure 4A). The status of MSI of the representative locus *D9S974* in three cell lines (AGS, HeLa, and MGC803) could be stably confirmed with clone-sequencing (Figure S3). Thus, we used the DHPLC assay to detect MSI at these microsatellite loci in GCs from another set of patients (*n*=140) using the paired SMs as the normal control (Figure 4B). The frequency of *CDKN2A* SCND by P16-Light was 38.6% in these GCs, while the MSI frequency of these loci by DHPLC were 22.9% for *D9S974*, 16.4% for *D9S942*, 17.9% for *D9S1748*, 32.9% for *D9S941*, 21.4% for *D9S1749*, and 10% for *D9S171*, respectively. And the positive rate of *CDKN2A* LOH was 35.7%. Both the frequency of *CDKN2A* LOH and SCND was significantly increased in GCs at advanced stages (*p*=0.017 and 0.036; Table 2). Notably, while *CDKN2A* SCND was significantly associated with distant metastasis of GCs (*p*=0.023), such association was not observed for *CDKN2A* LOH (*p*=0.213).

In addition, the frequency of *CDKN2A* SCND was higher in GCs with MSI of any of these 6 microsatellites or *CDKN2A* LOH than those without MSI (chi-square test, *p*=0.021 for *D9S941*; Figure 4C). More *CDKN2A* amplification was also detected in GCs with MSI at *D9S1748* than in those without (*p*<0.001; Figure 4D), consistent with that MSI represents both copy number deletion and amplification of host genes. These results suggest the advantage of P16-Light over DHPLC-LOH (or GOH) for detection of *CDKN2A* SCNVs as the prognosis biomarker.

Discussion

CDKN2A SCND is frequent in many human cancers. However, clinical applications of SCND of *CDKN2A* and other genes are rare. One of the major reseans is the lack of convenient detection approches for routine clinical use. Interstitial deletion/fusion is the main type of *CDKN2A* SCND and the breaking/fusing coordinates for *CDKN2A* SCNDs are diverse that blocks the establishment of a feasible assay for *CDKN2A* SCND detection, although many efforts have been afforded (25). In the present study, we characterized for the first time, a 5.1-kb CDR sequence at base resolution within the *CDKN2A* gene in human cancers, and confirmed this finding using WGS datasets for all of 18 gastric cancers containing *CDKN2A* SCND (12). We

also established a highly reproducible, convenient, quantitative PCR assay called P16-Light for *CDKN2A* SCNV detection with the detection limit of 20%.

WGS is generally used as a gold standard to study structural alterations of genomic DNAs, especially for insterstitial gene copy deletion/fusions. Because WGS is a cost assay and its accuracy is depend on sequencing depth, WGS at sequencing depth 36× should be considered as a hemi-quantitative assay. In our calling *CDKN2A* SCND coordiate processes, we found that 18 *CDKN2A* SCND coordiates were identified in 17 (10.8%) of 157 GCs, which is consistent with the frequency (11.4%) of homozygous deletion of *CDKN2A* in 422 GCs in WES or WGS sequencing datasets (Table S2) (37). The positive rate (25.6%) of *CDKN2A* SCND in 156 GCs with enough amounts of genomic DNA samples in the P16-Light analysis was more than two times of that of WGS. And the results of P16-Light analyses were significantly correlated with that of WGS. These phenomena suggest that P16-Light is a more sensitive, more convenient, and less costly assay relative to WGS.

DHPLC-LOH is also a sensitive assay. A set of microsattelite loci are routinely employed as STS markers to detect LOH of a gene. Hence, a set of PCR reactions and DHPLC separation/detection should be performed. Using three *CDKN2A*-flanking microsattelites as the STS marker set to detect LOH of *CDKN2A*, the LOH positive rate of *CDKN2A* was was similar to that of *CDKN2A* SCND. Both LOH and SCND of the gene were significantly associated with GC TNM stages. Because only *CDKN2A* SCND was significantly associated with GC metastasis and the occurence of LOH and SCND of *CDKN2A* were not significantly associated with each other in these GCs, we could not complelely exclude the posssibility that they might be two complementary assays.

The driver function of the *CDKN2A* gene in cancer development is enigmatic. $P16^{ink4a}$ inactivation contributes less than $P19^{arf}$ (the murine counterpart of human $P14^{ARF}$) inactivation to cancer development in mice while $P16^{INK4a}$ inactivation contributes more than $P14^{ARF}$ inactivation to cancer development in humans (38,39). The exact mechanisms leading to the difference among species is still unclear. Here, we reported that aproximately 87% of genetic $P16^{INK4a}$ inactivation is accompanied by $P14^{ARF}$ inactivation in human cancer cell lines or tissues. This may account for the species-related functional difference of the *CDKN2A* gene. This explanation is also supported by the report that knocking out both $p16^{ink4a}$ and $p19^{arf}$ leads to more cancer development than individual inactivation in mice (40).

Relative to the internal control *GAPDH* gene, the copy number of *CDKN2A* could be calculated in the P16-Light assay. A paired SM control sample was needed to be used to distinguish SCNVs from germline

changes. The sensitivity (or detection limit) for P16-Light was 20%, which could be further increased up to 6% when a droplet digital PCR platform was employed in the multiplex PCR reactions (data not shown). The results of our prospective cohort studies on both regression of esophageal squamous cell dysplasia (prepared for publication) and post-surgical metastasis of GCs (41) suggest that the sensitivity of 20% is good enough for routine clinical use.

In conclusion, we have, for the first time, found that there is a 5.1-kb CDR region within the *CDKN2A* gene, and that most *CDKN2A* deletions lead to *P16^{INK4a}* and *P14^{ARF}* coinactivation in human cancers. Using the CDR as a target sequence, we developed a convenient quantitative multiplex PCR assay, the P16-Light to detect *CDKN2A* SCNVs in clinical practice. In addition, we observed similar CDR regions within other tumor suppressor genes such as *ATM*, *FAT1*, *miR31HG*, *PTEN*, and *RB1* in the SNP array-based TCGA SCNV datasets (Figure S4), suggesting that our strategy to detect *CDKN2A* SCNVs may be suitable for the establishment of detection methods for other genes.

Abbreviations

CDR, common deletion region;

DHPLC, denaturing high performance liquid chromatography

GC, gastric carcinoma

LOH, loss of heterozygosity

MSI, microsatellite instability

OMIM, the Online Mendelian Inheritance in Man;

SCND, somatic copy number deletion

SM, surgical margin

TCGA, The Cancer Genome Atlas

WGS, whole genome sequencing

Ethical approval and consent to participate: The Institution Review Board of Peking University Cancer Hospital & Institute approved this study and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the study.

Consent for publication: Not applicable.

Availability of supporting data: Detailed information on the base-resolution interstitial common deletion region in the *CDKN2A* gene in 110 cancer samples was listed in Supplementary Table S1.

Competing Insterests: D.J.D., Y.T., J.Z., and Z.J.L are the creators for the pending patent "A quantitative method for detection of human CDKN2A gene copy number using a primer set and their applications" (PCT/CN2019/087172; WO2020228009). All of other authors have nothing to disclose.

Funding: This work was supported by the Beijing Natural Science Foundation (grant number 7181002 to D.J.D.); Beijing Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to D.J.D.).

Author contributions: D.J.D. designed the study, performed bioinformatics analyses, characterized base resolution *CDKN2A CDR* coordinates, and wrote the manuscript draft. J.Z., Y.T., Z.J.L., and L.K.G. developed the P16-Light assay and analyzed *CDKN2A* SCNVs in samples. R.X. and Y.Y.L. provided the *CDKN2A CDR* coordinates from whole genome sequencing datasets. All authors approved the final manuscript.

Acknowledgements: We thanks Dr. Sanford Dawsey at NCI, NIH, Bethesda, Maryland for critical comments for the manuscript. We also thanks Miss Gina Mckeown in New York, USA for English language editing.

Authors' information: Professor Dajun Deng was graduated from Peking Union Medical College in 1986 and employed by Peking University Cancer Hospital (Beijing Institute for Cancer Research) from then on. His current research activities are focused on genetic and epigenetic *CDKN2A* inactivation in cancer development. He published approximately 150 scientific papers, including Mol Cancer, Nucl Acids Res, Genome Biol, Proc Nat Acad Sci USA, Clin Cancer Res, and EBioMed. His ORCiD is 0000-0001-5161-5943.

References

1.   Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, et al. The landscape of somatic copy-number alteration across human cancers [eng]. Nature 2010 Feb;463 7283:899-905 as doi: 10.1038/nature08822.

2.   Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data [eng]. Cancer Discov 2012 May;2 5:401-4 as doi: 10.1158/2159-8290.CD-12-0095.

3.   Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers [eng]. Genome Biol 2011;12 4:R41. Epub 2011/04/28 as doi: 10.1186/gb-2011-12-4-r41.

4. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal [eng]. Sci Signal 2013 Apr;6 269:pl1. Epub 2013/04/02 as doi: 10.1126/scisignal.2004088.

5. Network CGAR, University AWGA, Agency BC, Hospital BaWs, Institute B, University B, University CWR, et al. Integrated genomic characterization of oesophageal carcinoma [eng]. Nature 2017 01 12;541 7636:169-75. Epub 20170104 as doi: 10.1038/nature20805.

6. Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma [eng]. Cell Res 2020 10;30 10:902-13. Epub 20200512 as doi: 10.1038/s41422-020-0333-6.

7. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho R. Role of the INK4a locus in tumor suppression and cell mortality. [eng]. Cell 1996 Apr;85 1:27-37.

8. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation [eng]. Cancer Discov 2018 02;8 2:216-33. Epub 2017/11/03 as doi: 10.1158/2159-8290.CD-17-0915.

9. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade [eng]. Cell 2018 11;175 4:984-97.e24 as doi: 10.1016/j.cell.2018.09.006.

10. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance [eng]. Nature 2018 01;553 7686:91-5. Epub 2017/11/16 as doi: 10.1038/nature25015.

11. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yin T, et al. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma [eng]. Clin Cancer Res 2019 Nov;25 21:6511-23. Epub 2019/08/02 as doi: 10.1158/1078-0432.CCR-19-0475.

12. Xing R, Zhou Y, Yu J, Yu Y, Nie Y, Luo W, Yang C, et al. Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer [eng]. Nat Commun 2019 05;10 1:2037. Epub 2019/05/02 as doi: 10.1038/s41467-019-09644-6.

13. Sobin, L., Gospodarowicz, M., Wittekind, C. (2009) TNM Classification of Malignant Tumours, 7th edn. International Union Against Cancer (UICC). Wiley Press, New York, USA.

14. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC, Weghorst CM. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia [eng]. Cancer Res 2002 Sep;62 18:5295-300.

15. Sabah M, Cummins R, Leader M, Kay E. Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors [eng]. Appl Immunohistochem Mol Morphol 2006 Mar;14 1:97-102 as doi: 10.1097/01.pai.0000143787.80564.f5.

16. Qin SS, Li Q, Zhou J, Liu ZJ, Su N, Wilson J, Lu ZM, et al. Homeostatic Maintenance of Allele-Specific p16 Methylation in Cancer Cells Accompanied by Dynamic Focal Methylation and Hydroxymethylation. Plos One 2014 May;9 5 as doi: 10.1371/journal.pone.0097785.

17. Kleymenova E, Walker CL. Determination of loss of heterozygosity in frozen and paraffin embedded tumors by denaturating high-performance liquid chromatography (DHPLC) [eng]. J Biochem Biophys Methods 2001 Jan 30;47 1-2:83-90 as doi: 10.1016/s0165-022x(00)00154-8..

18. Pan KF, Liu W, Lu YY, Zhang L, Li ZP, Lu WL, Thibodeau SN, et al. High throughput detection of microsatellite instability by denaturing high-performance liquid chromatography [eng]. Hum Mutat 2003 Nov;22 5:388-94 as doi: 10.1002/humu.10271.

19. Ezzeldin H, Hoffmayer C, Soong R, Johnson MR, Lee A, Heslin M, Diasio R. Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high-performance liquid chromatography [eng]. Anal Biochem 2004 Nov 15;334 2:276-83 as doi: 10.1016/j.ab.2004.07.025.

20. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours [eng]. Nat Genet 1995 Oct;11 2:210-2 as doi: 10.1038/ng1095-210.

21. Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood [eng]. Hum Genet 2009 Oct;126 4:511-20. Epub 20090530 as doi: 10.1007/s00439-009-0689-7.

22. Xie H, Rachakonda PS, Heidenreich B, Nagore E, Sucker A, Hemminki K, Schadendorf D, et al. Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts [eng]. Oncotarget 2016 Mar 29;7 13:16490-504 as doi: 10.18632/oncotarget.7503.

23. Norris AL, Kamiyama H, Makohon-Moore A, Pallavajjala A, Morsberger LA, Lee K, Batista D, et al. Transflip mutations produce deletions in pancreatic cancer [eng]. Genes Chromosomes Cancer 2015 Aug;54 8:472-81. Epub 20150529 as doi: 10.1002/gcc.22258.

24. Guney S, Bertrand P, Jardin F, Ruminy P, Kerckaert JP, Tilly H, Bastard C. Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas [eng]. Genes Chromosomes Cancer 2011 Sep;50 9:715-25. Epub 20110602 as doi: 10.1002/gcc.20893.

25. Patel A, Schwab R, Liu YT, Bafna V. Amplification and thrifty single-molecule sequencing of recurrent somatic structural variations [eng]. Genome Res 2014 Feb;24 2:318-28. Epub 20131204 as doi: 10.1101/gr.161497.113.

26. Florl AR, Schulz WA. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells [eng]. Genes Chromosomes Cancer 2003 Jun;37 2:141-8 as doi: 10.1002/gcc.10192.

27. Kitagawa Y, Inoue K, Sasaki S, Hayashi Y, Matsuo Y, Lieber MR, Mizoguchi H, et al. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia [eng]. J Biol Chem 2002 Nov 29;277 48:46289-97. Epub 20020912 as doi: 10.1074/jbc.M208353200.

28. Sasaki S, Kitagawa Y, Sekido Y, Minna JD, Kuwano H, Yokota J, Kohno T. Molecular processes of chromosome 9p21 deletions in human cancers [eng]. Oncogene 2003 Jun;22 24:3792-8 as doi: 10.1038/sj.onc.1206589.

29. Cayuela JM, Gardie B, Sigaux F. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias [eng]. Blood 1997 Nov 01;90 9:3720-6.

30. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF [eng]. Cancer Res 2007 Apr 15;67 8:3963-9 as doi: 10.1158/0008-5472.CAN-06-2004.

31. Raschke S, Balz V, Efferth T, Schulz WA, Florl AR. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines [eng]. Genes Chromosomes Cancer 2005 Jan;42 1:58-67 as doi: 10.1002/gcc.20119.

32. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, et al. Germline p16 mutations in familial melanoma [eng]. Nat Genet 1994 Sep;8 1:15-21 as doi: 10.1038/ng0994-15.

33. Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, et al. Frequent p16-independent inactivation of p14ARF in human melanoma [eng]. J Natl Cancer Inst 2008 Jun;100 11:784-95. Epub 2008/05/27 as doi: 10.1093/jnci/djn157.

34. Harinck F, Kluijt I, van der Stoep N, Oldenburg RA, Wagner A, Aalfs CM, Sijmons RH, et al. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas [eng]. J Med Genet 2012 Jun;49 6:362-5. Epub 2012/05/25 as doi: 10.1136/jmedgenet-2011-100563.

35. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders [eng]. Nucleic Acids Res 2005 Jan;33 Database issue:D514-7 as doi: 10.1093/nar/gki033.

36. Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick's Online Mendelian Inheritance in Man (OMIM) [eng]. Nucleic Acids Res 2009 Jan;37 Database issue:D793-6. Epub 2008/10/08 as doi: 10.1093/nar/gkn665.

37. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, et al. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas [eng]. Cancer Cell 2018 04 09;33 4:721-35.e8. Epub 20180402 as doi: 10.1016/j.ccell.2018.03.010.

38. Peters G. Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma [eng]. J Natl Cancer Inst 2008 Jun 04;100 11:757-9. Epub 20080527 as doi: 10.1093/jnci/djn156.

39. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming [eng]. Nature 2009 Aug 27;460 7259:1136-9. Epub 20090809 as doi: 10.1038/nature08290.

40. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis [eng]. Oncogene 2004 Jan;23 2:379-85 as doi: 10.1038/sj.onc.1207074.

41. Qiao JL, Tian Y, Cheng XJ, Liu ZJ, Zhou J, Gu LK, Zhang BZ, et al. CDKN2A deletion leading to hematogenous metastasis of human gastric carcinoma. Frontiers in Oncology 2021 Dec 06; DOI: 10.3389/fonc.2021.801219

Figures and Legends

Figure 1. Base resolution of the genomic coordinates of interstitial *CDKN2A* deletion/fusion in human cancers. The top chart displays the coordinates of whole deleted fragments by Sanger sequencing of chromosome 9p21 in *CDKN2A*-deleted cancer cell lines and tissue samples (*n*=92, blue lines), and in gastric carcinomas (GC, *n*=18, purple lines) by whole genome sequencing (WGS). The sample ID is labeled under each column. The bottom chart displays an amplified view of the *CDKN2A* gene, where the 5.1-kb common deletion region (CDR) occurred from the $P16^{INK2a}$ promoter to intron-2 (highlighted with a red dashed line rectangle), which is exactly the same region as the deleted *CDKN2A* fragment in the HCC193 lung cancer cell line (highlighted with a black line). The detailed deletion coordinates for each sample are listed in Table S1. Each line represents a *CDKN2A* deletion fragment. The locations of $P16^{INK4a}$ and $P14^{ARF}$ (green lines) and exon-1α/2/3 (black dots) are also labeled as landmarks.

Figure 2. Detection of the copy number of *CDKN2A* intron-2 with quantitative gene-specific multiplex PCR

(P16-Light). (**A**) The location of the 129-bp amplicon within the common deletion region (CDR) and its host

genes. (**B**) The amplication efficiency of two amplicons for *GAPDH* and *CDKN2A* genes in the template

titration assays using standard DNA samples from RKO cells (with two wild-type *CDKN2A* alleles) and A549

cells (with a homozygous *CDKN2A* deletion). (**C**) Effects of the amount of template DNA on the efficiency of

PCR amplification for amplicons in *CDKN2A* and *GAPDH* genes (Left chart) and detection of the relative

CDKN2A gene copy number (Right chart). (**D**) The linear relationship between the proportion of *CDKN2A* copy number deletion and ratios of RKO cells spiked with A549 cells. (**E**) Stability of the proportion of the *CDKN2A* copy number deletion by P16-Light during ten experiments over different days. The RKO cell DNA templates were spiked with 0, 10%, 20%, 25%, and 30% A549 cell DNA. Each column represents the average proportion of *CDKN2A* copy number deletion in triplicate. Exp. 1 - 10: the results of 10 repeated experiments performed on different days. *: compared to the 100% RKO control in chi-square test, *p*<0.05.

2 **Figure 3.** Comparisons of somatic copy number variations (SCNVs) of *CDKN2A* gene in gastric carcinoma

3 samples (*n*=156) relative to the paired normal control in the P16-Light and WGS (30×) analyses

Figure 4. The results of the microsatellite instability (MSI) of the *CDKN2A* gene and neighboring regions in gastric carcinoma samples by three common deletion region (CDR) flanking microsatellites (*D9S974*, *D9S942*, and *D9S1748*) within the *CDKN2A* gene and three non-*CDKN2A* microsatellites (*D9S941*, *DS749*, and *D9S171*) outside of the *CDKN2A* gene. (**A**) The graphic views for the locations of the 5.1-kb CDR and microsatellites at 9p21 are illustrated. Each red arrowed line represents a gene and its transcription direction. (**B**) The informative chromatograms for the PCR products of various microsatellites in gastric cancer and the paired normal tissues from a representative patients with denaturing high-performance liquid chromatography (DHPLC, sizing model) at 50°C. Blue line: gastric carcinoma tissue; red line: paired surgical margin tissue. (**C**) The positive rate of somatic *CDKN2A* copy number deletion in informative GCs with and without LOH of 6 microsatellites and their combination (Any locus); (**D**) The positive rate of somatic *CDKN2A* copy number amplification in 140 informative GCs with and without LOH of 6 microsatellites and their combination. Statistically significant *p*-values in chi-square tests were also labeled.

Table 1. Oligo sequences

Gene/STS	Assay	Oligo	Sequence (5'-3')	PCR product size
CDKN2A	P16-Light	F-primer	caggtctgtttcctcatttg	129-bp
		R-primer	ggtcagattagttgagttgtg	
		Probe	FAM-ctggctggaccaacctcagg-BHQ1	
GAPDH	P16-Light	F-primer	gctcacatattctggaggag	135-bp
		R-primer	ggtcattgatggcaacaata	
		Probe	Cy5-tgccttcttgcctcttgtctctt-BHQ2	
D9S941	MSI/DHPLC	Forward	aaaaaaaggaagggaggagg	205-bp
		Reverse	acaccggatgaagtcaccta	
D9S1749	MSI/DHPLC	Forward	aggagagggtacgcttgcaa	120-bp
		Reverse	tacagggtgcgggtgcagataa	
D9S974	MSI/DHPLC	Forward	gagcctggtctggatcataa	190-bp
		Reverse	aagcttacagaaccagacag	
D9S942	MSI/DHPLC	Forward	gcaagattccaaacagta	100-bp
		Reverse	ctcatcctgcggaaaccatt	
D9S1748	MSI/DHPLC	Forward	cacctcagaagtcagtgagt	130-bp
		Reverse	gtgcttgaaatacacctttcc	
D9S171	MSI/DHPLC	Forward	agctaagtgaacctcatctctgtct	158-177-bp
		Reverse	accctagcactgatggtatagtct	

Table 2. Association between clinicopathological characteristics and instability at various microsatellite loci within and not within the *CDKN2A* gene by DHPLC and somatic copy number variations of *CDKN2A* gene by P16-Light

		n	*CDKN2A* LOH (%)	Microsatellite instability (MSI) by DHPLC (%)						*CDKN2A* SCNV by P16-Light (%)		
				D9S941	D9S1749	D9S974	D9S942	D9S1748	D9S171	Amplified	Diploid	Deleted
Age	<60	70	23 (32.9)	19 (27.1)	14 (20.0)	12 (17.1)	12 (17.1)	13 (18.6)	7 (10.0)	7 (10.0)	38 (54.3)	25 (35.7)
	≥60	70	27 (38.6)	27 (38.6)	16 (22.9)	20 (28.6)	11 (15.7)	12 (17.1)	7 (10.0)	9 (12.9)	32 (45.7)	29 (41.4)
Sex	Male	104	36 (34.6)	35 (33.7)	20 (19.2)	26 (25.0)	16 (15.4)	16 (15.4)	9 (8.7)	13 (12.5)	49 (47.1)	42 (40.4)
	Female	36	14 (38.9	11 (30.6)	10 (27.8)	6 (16.7)	7 (19.4)	9 (25.0)	5 (13.9)	3 (8.3)	21 (58.3)	12 (33.3)
Location[a]	Proximal	71	26 (36.6)	**30 (42.3)[b]**	17 (23.9)	16 (22.5)	12 (16.9)	11 (15.5)	6 (8.5)	7 (9.9)	37 (52.1)	27 (38.0)
	Distal	69	24 (34.8)	**16 (23.3)**	13 (18.8)	16 (23.2)	11 (15.9)	14 (20.3)	8 (11.6)	9 (13.0)	33 (47.8)	22 (31.9)
Different.	Poor	102	35 (34.3)	32 (31.4)	21 (20.6)	21 (20.6)	17 (16.7)	17 (16.7)	13 (12.7)	11 (10.8)	45 (44.1)	46 (45.1)
	Well/mod.	38	15 (39.5)	14 (36.8)	9 (23.7)	11 (28.9)	6 (15.8)	8 (21.1)	1 (2.6)	5 (13.2)	9 (23.7)	24 (63.2)
Vascular embolus	Negative	61	**16 (26.2)[c]**	18 (29.5)	11 (18.0)	10 (16.4)	6 (9.8)	10 (16.4)	7 (11.5)	9 (14.8)	32 (52.5)	20 (32.8)
	Positive	79	**34 (43.0)**	28 (35.4)	19 (24.1)	22 (27.8)	17 (21.5)	15 (19.0)	7 (8.9)	7 (8.9)	38 (48.1)	34 (43.0)
pTNM stage	I-II	47	**11 (23.4)[d]**	11 (23.4)	7 (14.9)	9 (19.1)	**3 (6.4)[e]**	5 (10.6)	4 (8.5)	4 (8.8)	30 (63.8)	**13 (27.7)[f]**
	III	39	**14 (35.9)**	14 (35.9)	10 (25.6)	6 (15.4)	**7 (17.9)**	8 (20.5)	5 (12.8)	4 (10.3)	20 (51.3)	**15 (38.5)**
	IV	54	**25 (46.3)**	21 (38.9)	13 (24.1)	17 (31.5)	**13 (24.1)**	12 (22.2)	5 (9.3)	8 (14.8)	20 (37.0)	**26 (48.1)**
Invasion	T1-2	25	8 (32.0)	8 (32.0)	7 (28.0)	6 (24.0)	3 (12.0)	5 (20.0)	1 (4.0)	1 (4.0)	13 (52.0)	11 (44.0)
	T3	82	27 (32.9)	26 (31.7)	16 (19.5)	17 (20.7)	11 (13.4)	14 (17.1)	10 (12.2)	8 (9.8)	42 (51.2)	30 (36.6)
	T4	33	15 (45.5)	12 (36.4)	7 (21.2)	9 (27.3)	9 (27.3)	6 (18.2)	3 (9.1)	7 (21.2)	15 (45.5)	13 (39.4)
Lymph metast.	Negative	50	14 (28.0)	13 (26.0)	10 (20.0)	9 (18.0)	7 (14.0)	8 (16.0)	5 (10.0)	5 (10.0)	23 (46.0)	22 (44.0)
	Positive	90	36 (40.0)	33 (36.7)	20 (22.2)	23 (25.6)	16 (17.8)	17 (18.9)	9 (10.0)	11 (12.2)	47 (52.2)	32 (35.6)
Distant metast.	Negative	109	36 (33.0)	37 (33.9)	22 (20.2)	25 (22.9)	17 (15.6)	18 (16.5)	13 (11.9)	**13 (11.9)**	**62 (56.9)**	**36 (33.0)[g]**
	Positive	31	14 (45.2)	9 (29.0)	8 (25.8)	7 (22.6)	6 (19.4)	7 (22.6)	1 (3.2)	**3 (9.4)**	**8 (25.8)**	**18 (58.1)**
(Total)		140	50 (35.7)	46 (32.9)	30 (21.4)	32 (22.9)	23 (16.4)	25 (17.9)	14 (10.0)	16 (11.4)	70 (50.0)	54 (38.6)

[a,] Proximal, Cardia/Funfus/Body/Greater curvature; Distal, Antrum/Lesser curvature;

[b/c/d/e/f/g,] Chi-square test, *p*=0.016/0.040/0.017/0.018/0.036/0.023

1   Supplementary Data

Supplemental data include four figures and two tables.

Figure S1. Prevalence of *CDKN2A* deep-deletion and the levels of gene expression in 10967 samples from

cancer patients in Pan-TCGA studies. (**A**) Prevalence of *CDKN2A* deep deletion detected by Affymetrix

SNP6.0 microarray. The number of total cancer cases and cases with *CDKN2A* deep deletion are listed for

each kind of cancer. (**B**) The levels of *P16^{INK4a}* mRNA determined by RNA sequencing in cancers with various

CDKN2A genetic changes. The charts for patients (n=10953) in 32 Pan-TCGA studies were adapted from a

graphic view at the cBioPortal Cancer Genomics website (www.cbioportal.org).

Figure S2. Distribution pattern of the Online Mendelian Inheritance in Man (OMIM) allelic variants within

the *CDKN2A* common deletion region (CDR, highlighted in blue shadow). 12 allelic variants are located in

CDKN2A exon-2, 2 allelic variants are located in *CDKN2A* exon-1α, and 1 allelic variant is located in *CDKN2A*

exon-1β. This chart was adapted from the UCSC Genome Browser on March 10, 2021.

Figure S3. Chromatograms for the microsatellite *D9S974* in human cancer cell lines AGS, HeLa, and MGC803. (**A**)

DHPLC chromatograms detected at 50°C; (**B**) the results of clone-sequencing

Figure S4. Approximate locations of the estimated common deletion fragment within tumor suppressor genes

ATM, *FAT1*, *RB1*, *PTEN*, and *miR31HG* in TCGA pan-cancers (by Affymetrix SNP6.0 microarray).

Table S1. Base-resolution coordinates for *CDKN2A* deletions in 110 cancer samples

Table S2. *CDKN2A* homozygous deletion in STADs from patients in TCGA cohort